Nuvectis Pharma Inc
nuvectis.comWhat Do They Do?
Develops targeted small-molecule drug candidates to treat cancer in patients with serious oncology conditions.
10-K for FY2025, filed Feb 11, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 11, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$7MView ↗
- ▲ +11% (Loss)
- vs −$6.3M in Q2 FY2025
-
Aug 4, 2026
NXP100 received marketing approval in China
The approval covers patients with paroxysmal nocturnal hemoglobinuria who had not previously received complement inhibitors.
Sources
8-K, filed Aug 4, 2026
The Company’s lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, oral administration, was approved…View ↗
-
Jun 23, 2026
Licensed development and commercialization rights to NXP100 and NXP200 from Haisco
Sources
8-K, filed Jun 23, 2026
On June 22, 2026, Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), entered into a license agreement (the “License Agreement”)…View ↗
Ended development of the ovarian cancer drug
The older report identifies its ovarian cancer drug as the lead and outlines another cancer candidate; the latest says development of the ovarian cancer drug ceased and focuses on advancing the other candidate.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Feb 11, 2026
Who Do They Compete With?
Competes with AstraZeneca
10-K for FY2025, filed Feb 11, 2026In the SRC/YES1 space, Dasatinib (SPRYCEL®) and bosutinib (BOSULIF®) are multi-kinase inhibitors that potently inhibit the catalytic…View ↗
Loading...
